Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 51Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 38Neoplasm Metastasis 20Carcinoma, Hepatocellular 20Lung Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Neoplasms 17Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Esophageal Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Breast Neoplasms 7Recurrence 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Uveal Melanoma 5Uterine Cervical Neoplasms 5

Interventions

liposomal doxorubicin 1fludarabine 1dostarlimab 1Paclitaxel 1Nivolumab 1Ipilimumab 1Gemcitabine 1Doxorubicin 1Dexamethasone 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Nivolumab × 90 days × Clear all
NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Brown University

Phase 2 Active not recruiting
46 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡